Intel stock spikes after report of possible US government stake
Frank H. Laukien, President and CEO of Bruker Corporation (NASDAQ:BRKR), recently purchased a significant amount of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Laukien acquired a total of 20,000 shares on February 18, 2025. The transaction, which occurred in two separate purchases, involved shares bought at prices ranging from $50.75 to $51.23 per share, amounting to a total investment of approximately $1.02 million. This insider purchase comes as the stock trades near its 52-week low of $48.07, having declined about 38% over the past year. InvestingPro analysis suggests the stock is currently slightly undervalued based on its proprietary Fair Value model.
Following these transactions, Laukien’s direct ownership of Bruker stock increased to 38,459,563 shares. Additionally, the filing disclosed indirect holdings, including shares held by family members and as a custodian, further highlighting Laukien’s substantial stake in the company. With a market capitalization of $7.81 billion, InvestingPro subscribers can access additional insights through the comprehensive Pro Research Report, which includes detailed analysis of insider transactions, valuation metrics, and future growth prospects among 8+ key InvestingPro Tips.
In other recent news, Bruker Corporation reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.76 against the forecast of $0.74. Revenue also exceeded projections, reaching $979.6 million compared to the expected $962.38 million, marking a 14.6% year-over-year increase in quarterly revenue. Despite these positive results, Bruker’s stock experienced a slight decline. The company continues to focus on strategic acquisitions and innovation, with guidance for 2025 showing expected revenue growth and margin expansion. Bruker projects revenue between $3.47 billion and $3.54 billion for 2025, with anticipated organic revenue growth of 3-4%. Analyst firms have noted that Bruker’s strategic acquisitions and product innovations have bolstered its competitive position in key markets. The company has also highlighted its commitment to expanding its operating margin by more than 125 basis points annually. Risks such as NIH funding uncertainty and global economic conditions could impact future revenue streams, but Bruker remains optimistic about gradual recovery in the biopharma sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.